LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 3 | E24 | 72 | hr | 1401 | 3649 | 4545 | 0.8027 | 0.7571 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 1 | E23 | 72 | hr | 1401 | 3080 | 3978 | 0.7742 | 0.6872 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 2 | E23 | 72 | hr | 1401 | 3529 | 4213 | 0.8376 | 0.7888 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 3 | E23 | 72 | hr | 1401 | 3546 | 4545 | 0.7800 | 0.7277 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 1 | E22 | 72 | hr | 1401 | 2391 | 3978 | 0.6010 | 0.4260 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 2 | E22 | 72 | hr | 1401 | 2408 | 4213 | 0.5715 | 0.4061 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 3 | E22 | 72 | hr | 1401 | 2801 | 4545 | 0.6162 | 0.5036 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 1401 | 2088 | 3978 | 0.5248 | 0.3032 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 2 | E21 | 72 | hr | 1401 | 2359 | 4213 | 0.5599 | 0.3880 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 1401 | 2644 | 4545 | 0.5816 | 0.4534 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 1 | E20 | 72 | hr | 1401 | 2051 | 3978 | 0.5155 | 0.2878 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 2 | E20 | 72 | hr | 1401 | 2209 | 4213 | 0.5243 | 0.3318 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 3 | E20 | 72 | hr | 1401 | 2065 | 4545 | 0.4543 | 0.2565 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 1 | E19 | 72 | hr | 1401 | 1615 | 3978 | 0.4059 | 0.0988 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 2 | E19 | 72 | hr | 1401 | 1967 | 4213 | 0.4669 | 0.2379 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 3 | E19 | 72 | hr | 1401 | 2039 | 4545 | 0.4485 | 0.2471 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 1 | F24 | 72 | hr | 1401 | 2993 | 3978 | 0.7523 | 0.6554 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 2 | F24 | 72 | hr | 1401 | 3174 | 4213 | 0.7533 | 0.6733 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 3 | F24 | 72 | hr | 1401 | 3166 | 4545 | 0.6965 | 0.6161 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 1 | F23 | 72 | hr | 1401 | 2627 | 3978 | 0.6603 | 0.5180 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 2 | F23 | 72 | hr | 1401 | 2838 | 4213 | 0.6736 | 0.5594 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 3 | F23 | 72 | hr | 1401 | 3333 | 4545 | 0.7332 | 0.6658 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 1 | F22 | 72 | hr | 1401 | 3081 | 3978 | 0.7744 | 0.6876 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 2 | F22 | 72 | hr | 1401 | 3166 | 4213 | 0.7514 | 0.6706 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 3 | F22 | 72 | hr | 1401 | 2568 | 4545 | 0.5649 | 0.4286 |